Pharmacogenetics for type 2 diabetes: practical considerations for study design.
There is a relative dearth of studies designed to elucidate genetic variation that can explain differences in the response to diabetes pharmacotherapy. When designing such studies, appropriate consideration of the various nongenetic variables that can affect the treatment response is necessary. In addition, disease stage and prior pharmacotherapy also influence drug efficacy. Selecting the appropriate genetic variant to test in such studies is also important, and common variants (known to be functional or otherwise) in a given candidate locus should be tested for the effect on the treatment response. Finally, an appropriate measure of treatment response is necessary to enable detection of pharmacogenetic effects. Perhaps prior to undertaking such studies, smaller studies utilizing well-characterized, homogenous populations with normal glucose tolerance or prediabetes (to avoid the problem of disease effects on treatment response) and surrogate measures of response such as insulin secretion should be completed.
Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota 55905, USA. vella.adrian@mayo.edu
Adrian
A
Vella
D003924:Diabetes Mellitus, Type 2 / Q000235:genetics* / Q000628:therapy; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D006801:Humans; D010597:Pharmacogenetics; D012107:Research Design